Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THRV-1268 in healthy obese adults
NCT07186946Phase 1Completed
- Sponsor
- Thryv Therapeutics Inc.
- Start
- Sep 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of THRV-1268 in heart failure (HF) (2 arms), sponsored by Thryv Therapeutics Inc. Primary endpoint: Safety and Tolerability of Single Oral Dose at 7 days. Started Sep 2025; status: completed.
02
Drugs
THRV-1268
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT07186946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07186946.